For the analysis, the team evaluated almost 1,000 cases of patients with skin manifestations of COVID-19 in collaboration with the International League of Dermatological Societies and the American Academy of Dermatology.
The median duration of skin symptoms, among 224 total suspected cases and 90 laboratory-confirmed cases of COVID-19 from 39 countries, was 12 days.
Rash-like morbilliform and urticarial eruptions lasted a median of 4-7 days and a maximum duration of 28 days for patients with lab-confirmed COVID-19. Papulosquamous eruptions (scaly papules and plaques) lasted a median of 20 days in lab-confirmed cases, with one confirmed long hauler eruption lasting 70 days.
Pernio/chilblains, or redness and swelling of the feet and hands, commonly known as “COVID toes,” lasted a median of 15 days in patients with suspected COVID-19 and 10 days in lab-confirmed cases.
Notably, six patients with pernio/chilblains were long haulers with toe symptoms lasting at least 60 days, with two lab-confirmed patients with COVID toes lasting longer than 130 days.
Senior author Esther E. Freeman, MD, PhD, director of Global Health Dermatology at MGH, said: “Our findings reveal a previously unreported subset of patients with long-standing skin symptoms from COVID-19, in particular those with COVID toes. This data adds to our knowledge about the long-term effects of COVID-19 in different organ systems. The skin is potentially a visible window into inflammation that could be going on in the body.
“We encourage clinicians taking care of patients with COVID-19 to ask about and evaluate any skin symptoms. Health care providers can enter information into our registry to further our understanding of the dermatologic effects of COVID-19.”
The team defined long haulers as anyone with skin symptoms of COVID-19 that persisted for at least 60 days.
Editor's Recommended Articles
Must Read >> New research explores the mutation of COVID-19